» Authors » Douglas C Bauer

Douglas C Bauer

Explore the profile of Douglas C Bauer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 327
Citations 13482
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Schini M, Vilaca T, Vittinghoff E, Lui L, Ewing S, Thompson A, et al.
J Bone Miner Res . 2024 Mar; 39(5):544-550. PMID: 38501786
There is a common belief that antiosteoporosis medications are less effective in older adults. This study used data from randomized controlled trials (RCTs) to determine whether the anti-fracture efficacy of...
12.
Tramontana F, Napoli N, Litwack-Harrison S, Bauer D, Orwoll E, Cauley J, et al.
J Clin Endocrinol Metab . 2024 Feb; 109(12):e2283-e2290. PMID: 38407631
Context: Type 2 diabetes mellitus is associated with more rapid bone loss in women, but less evidence is available for men or those with prediabetes. Objective: To determine whether bone...
13.
Snyder P, Bauer D, Ellenberg S, Cauley J, Buhr K, Bhasin S, et al.
N Engl J Med . 2024 Jan; 390(3):203-211. PMID: 38231621
Background: Testosterone treatment in men with hypogonadism improves bone density and quality, but trials with a sufficiently large sample and a sufficiently long duration to determine the effect of testosterone...
14.
Bauer D, Black D, Dell R, Fan B, Smith C, Ernst M, et al.
J Clin Endocrinol Metab . 2024 Jan; 109(11):e2141-e2150. PMID: 38198798
Context: Prolonged bisphosphonate (BP) treatment for osteoporosis prevents hip and other fractures but causes atypical femoral fractures (AFF). Objective: To establish the relationship between patterns of BP use and the...
15.
Xu Y, Derakhshan A, Hysaj O, Wildisen L, Ittermann T, Pingitore A, et al.
Lancet Diabetes Endocrinol . 2023 Sep; 11(10):743-754. PMID: 37696273
Background: Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT) are statistically defined by the 2·5-97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define...
16.
Marriott R, Murray K, Adams R, Antonio L, Ballantyne C, Bauer D, et al.
Ann Intern Med . 2023 Aug; 176(9):1221-1234. PMID: 37639720
Background: Various factors modulate circulating testosterone in men, affecting interpretation of testosterone measurements. Purpose: To clarify factors associated with variations in sex hormone concentrations. Data Sources: Systematic literature searches (to...
17.
Saslow L, Eslamian A, Moran P, Hartogensis W, Mason A, Kim S, et al.
Trials . 2023 Jul; 24(1):463. PMID: 37475033
Background: Optimal carbohydrate intake is an important and controversial area in the nutritional management of type 2 diabetes. Some evidence indicates that reducing overall carbohydrate intake with a low- or...
18.
Buhrer J, Del Giovane C, Gencer B, Adam L, Lyko C, Feller M, et al.
Mayo Clin Proc Innov Qual Outcomes . 2023 Jun; 7(4):231-240. PMID: 37304064
Objective: To assess how inadequate reporting of cointerventions influences estimated treatment effects in recent cardiovascular trials. Methods: Medline/Embase were systematically searched from January 1, 2011 to July 1, 2021 for...
19.
Chan L, Chen L, Goldman M, Mak J, Bauer D, Boscardin J, et al.
Obstet Gynecol . 2023 Jun; 142(1):160-169. PMID: 37290104
Objective: To evaluate the effect of risk-reducing salpingo-oophorectomy (RRSO) on change in bone mineral density (BMD) in women aged 34-50 years with pathogenic variants in BRCA1 or BRCA2 ( BRCA1...
20.
Ribero V, Alwan H, Efthimiou O, Abolhassani N, Bauer D, Henrard S, et al.
medRxiv . 2023 Mar; PMID: 36993427
Introduction: Older and multimorbid adults with type 2 diabetes (T2D) are at high risk of cardiovascular disease (CVD) and chronic kidney disease (CKD). Estimating risk and preventing CVD is a...